Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

99.26B

Market cap99.26B

Price-Earnings ratio

20.22

Price-Earnings ratio20.22

Dividend yield

0.40%

Dividend yield0.40%

Average volume

1.31M

Average volume1.31M

High today

$969.00

High today$969.00

Low today

$859.50

Low today$859.50

Open price

$905.49

Open price$905.49

Volume

1.23M

Volume1.23M

52 Week high

$991.73

52 Week high$991.73

52 Week low

$591.52

52 Week low$591.52

Stock Snapshot

Regeneron(REGN) stock is priced at $969.00, giving the company a market capitalization of 99.26B. It carries a P/E multiple of 20.22 and pays a dividend yield of 0.40%.

On 2026-11-11, Regeneron(REGN) stock moved within a range of $859.50 to $969.00. With shares now at $969.00, the stock is trading +12.7% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 1.23M, compared to an average daily volume of 1.31M.

The stock's 52-week range extends from a low of $591.52 to a high of $991.73.

REGN News

Investing.com 13h

Jefferies reiterates Regeneron stock rating ahead of patent hearing - Investing.com

...

TipRanks 18h

Regeneron’s MASH Pipeline Supports Buy Rating; Price Target Unchanged at $1,030

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Regeneron. The associated price target remains the same with $1,030.00....

Simply Wall St 1d

Is Regeneron Pharmaceuticals Expensive On Promising CIDEBsiRNA Liver Disease Data?

Regeneron Pharmaceuticals (REGN) has put its early liver disease program in the spotlight after first in human data showed that a single CIDEBsiRNA dose reduced...

Analyst ratings

67%

of 30 ratings

Buy

66.7%

Hold

30%

Sell

3.3%

More REGN News

24/7 Wall St. 1d

Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Simply Wall St 3d

We Like The Quality Of Regeneron Pharmaceuticals' Earnings

Investors signalled that they were pleased with Regeneron Pharmaceuticals, Inc.'s ( ) most recent earnings report. This reaction by the market reaction is under...

Simply Wall St 6d

Regeneron Stock May Trade At A Discount Following Strong Q3 Earnings

has rallied hard over the past few years, and fresh earnings headlines keep pulling investor attention back to the same issue. With the share price moving quick...

TipRanks 7d

Regeneron Advances ALN-CIDEB Into Phase 3 Liver Disease Study

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is testing ALN-CIDEB in adults...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.